Research and Markets: Global Type 1 Diabetes Market 2014-2018 With Astrazeneca, Eli Lilly and Co, Novo Nordisk A/S & Sanofi-Aventis US Dominating

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/zwlsd2/global_type_1) has announced the addition of the "Global Type 1 Diabetes Market 2014-2018 with Astrazeneca, Eli Lilly and Co, Novo Nordisk A/S & Sanofi-Aventis US Dominating" report to their offering.

The Global Type 1 Diabetes Market will grow at a CAGR of 6.9% over the period 2013-2018.

One of the main drivers in this market is the increase in the global type 1 diabetic population. The global type 1 diabetes population is increasing every year with an annual increase of 3 percent in children below 14 years of age. An increase in the type 1 diabetic population might increase the number of people opting for treatment. This will drive the sale and revenue of these drugs.

The key vendors in the Global Type 1 Diabetes market are increasing their penetration in the emerging markets. Recent years have witnessed an increase in investment in manufacturing sites based in these countries with the intention to enhance the production of drugs such as insulin for local or global markets. For instance, the Frankfurt site is a key manufacturer for Sanofi diabetes products. However, Sanofi has invested in Russia for its Orel-based site to enable the production of insulin prefilled devices. For a similar category of products, Sanofi has also invested in a manufacturing site in Beijing to penetrate the market. Recently, Sanofi transferred the manufacturing technologies for Insuman insulin to Shantha Biotech in India (part of the Sanofi group). In 2009, Novo Nordisk completely transferred the production of NovoPen from Denmark to Tianjin. Also, in 2008, Novo Nordisk started the construction of an advanced insulin filling plant in Tianjin, which is expected to cater to the demand of the Chinese market for Penfill, the insulin based solution for injection in cartridges.

Further, the report states that one of the major challenges is the side effects of current therapies for type 1 diabetes. A lack of effective treatment that can manage glucose levels without causing adverse effects considerably decreases effective disease management.

Key Vendors

  • Astrazeneca plc
  • Eli Lilly and Co.
  • Novo Nordisk A/S
  • Sanofi-Aventis US LLC

Other Prominent Vendors

  • Biodel Inc.
  • Diamyd Medical AB
  • DiaVacs Inc.
  • Generex Biotechnology Corp.
  • Lexicon Pharmaceuticals Inc.
  • Macrogenics Inc.
  • MannKind Corp.
  • Osiris Therapeutics Inc.
  • Tolerion Inc.
  • XOMA Corp.

For more information visit http://www.researchandmarkets.com/research/zwlsd2/global_type_1

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices